Adaptive Biotechnologies (ADPT) shares surged nearly 37% in recent Friday trading, a day after the company reported a narrower loss and higher revenue in Q1.
The company reported a Q1 diluted loss late Thursday of $0.20 per share, narrowing from a loss of $0.33 a year earlier.
Analysts polled by FactSet expected a loss of $0.29.
Revenue for the quarter ended March 31 was $52.4 million, up from $41.9 million a year earlier.
Analysts surveyed by FactSet expected $42.7 million.
The company raised its full-year revenue guidance for the Minimal Residual Disease business to $180 million to $190 million from $175 million to $185 million previously. The company did not provide revenue guidance for its Immune Medicine business.
Analysts surveyed by FactSet expect total revenue of $216 million for the year.
The company also said it now expects full-year total company cash burn at $50 million to $60 million, versus $60 million to $70 million previously.
Price: 10.06, Change: +2.70, Percent Change: +36.71
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。